5323212026-10-312026-10-315323212026-10-315323212026-10-31ChangeInManagementDomain15323212026-10-312026-10-31ChangeInManagementDomain15323212026-10-31ChangeInManagementDomain25323212026-10-312026-10-31ChangeInManagementDomain2xbrli:pureZYDUSLIFEZYDUS LIFESCIENCES LIMITED532321NOTLISTEDINE010B01027trueListed Entity (self)false2026-10-3118:30:0022026-10-31CessationResignationSenior Management PersonnelPresident and Business Unit Head, International Markets BusinessMr.Amrut Naik2026-11-07falseAppointmentSenior Management PersonnelPresident and Business Unit Head, International Markets BusinessMr.Christoph Stoller2026-11-02Mr. Christoph Stoller is a highly accomplished Swiss pharmaceutical industry leader with more than 30 years of global experience in branded pharmaceuticals, specialty medicines, biologics, biosimilars, generics, OTC products, and innovative therapies. He has held CEO, President, Board, and Global Business Leadership roles across Europe, Emerging Markets, LATAM, and APAC. Educational qualification: Degree in Business Administration, Economics, Law, and Social Sciences from the University of St. Gallen, Switzerland, one of Europe's most respected business schools. Previous role • President & Business Head (EMEA, LATAM & APAC) at Glenmark Pharmaceuticals. • Member of Glenmark's Global Leadership Team. • Leading approximately 2,000 employees across 80 countries with P&L responsibility exceeding USD 750 million. Major Career Highlights • Doubled European revenue at Glenmark from approximately USD 200 million and significantly improved EBITDA performance. • Led commercialization and expansion of innovative products across international markets. • Member of Glenmark's AI Steering Committee driving business transformation initiatives. Previous leadership roles Teva Pharmaceuticals (2011-2021) • Senior Vice President & Cluster General Manager, Germany & Austria. • Senior Vice President, Generics & Commercial Operations Europe. • Managed businesses with up to USD 2 billion P&L and around 2,700 employees. • Led the European integration of Teva's acquisition of Actavis. • Delivered major profitability improvements, market access initiatives, and large-scale transformation programs. Helvepharm AG • CEO and member of the Executive Committee of Zur Rose Group. • Successfully transformed the company from a loss-making business into a highly profitable organization with strong value creation. Earlier Career Leadership roles at Roche Pharma, DSM Nutritional Products, and Swiss Re. Industry Leadership & Governance • Former President of Medicines for Europe (2019-2021), the leading European association representing generic and biosimilar medicine companies responsible for supplying approximately 70% of medicines in Europe. • Held Vice President and Executive Committee positions within the same organization. • Former Vice Chairman of Progenerika (Germany) and Board Member of Intergenerika (Switzerland). Education.